End of Compounded Semaglutide; 464M Teens Will Have Obesity; GLP-1 Scripts Skyrocket
(MedPage Today) — A federal deadline ending the sale of compounded semaglutide (Ozempic, Wegovy) is now in effect after a similar one for tirzepatide (Mounjaro, Zepbound) passed in March. (U.S. News & World Report) A patient-delivered lifestyle…
Glucagon-like peptide 1 level and risk of death within 90 days after intensive care unit admission: A substudy of the IVOIRE cohort
by Marine Jacquier, Annabelle Tavernier, Jean-Pierre Quenot, David Masson, Elea Ksiazek, Isabelle Fournel, Jacques Grober Background Elevated plasma levels of glucagon-like peptide-1 (GLP-1) have been associated with poor clinical outcome in patients with sepsis. This study investigated the association between GLP-1 levels, and survival at 90 days in a large cohort of critically ill patients. […]
Mochi Health Launches Insurance-Based Plans, Expanding Access to Personalized Obesity Care with Behavioral Therapy
What You Should Know: – Mochi Health, a physician-guided obesity care program, announced the launch of its new insurance-based plans. – These expanded offerings are designed to provide more personalized treatment experiences for patients, placing a strong emphasis on comprehensive obesity care that spans all aspects of an individual’s health. – The new insurance-based plans […]
In an Era of Mistrust on Health Information, Employers Are Key
In an era of growing mistrust, employers hold a unique position of influence. They remain among the most trusted institutions, particularly by their own employees. According to the 2024 Edelman Trust Barometer, workers consider businesses to be twice as competent as the U.S. government in providing credible information—outpacing nonprofits and the media as well. People […]
Ozempic Smell: What to know about latest side effect of weight loss drugs
Users of GLP-1 weight loss drugs report changes in their sense of smell, craving sweeter scents like vanilla and caramel.
GLP-1 Drug Use Surges 600% as 2% of Americans Take Weight-Loss Medications
An anonymous reader shares a report: More than 2% of Americans are taking the blockbuster class of GLP-1 drugs for overweight or obesity, up nearly 600% over six years, according to a report from FAIR Health given to Axios first. The data from FAIR Health’s repository of over 51 billion commercial healthcare claim records shows […]
What’s the Price Outlook for Weight-Loss Drugs?
The supply of GLP-1 drugs like Ozempic has been increasing, but they’re still expensive for most patients. Here are answers to some questions consumers have. Continuing high prices and demand for GLP-1 weight-loss drugs is creating lots of questions about the affordability of these drugs for U.S. …
Mochi Health Launches Insurance-Based Plans, Expanding Access to Personalized Obesity Care with Behavioral Therapy
What You Should Know: – Mochi Health, a physician-guided obesity care program, announced the launch of its new insurance-based plans. – These expanded offerings are designed to provide more personalized treatment experiences for patients, placing a strong emphasis on comprehensive obesity care that spans all aspects of an individual’s health. – The new insurance-based plans […]
Comedian Jim Gaffigan admits he lost 50 pounds using Mounjaro
Jim Gaffigan shared his weight loss journey with Mounjaro, as he shed 50 pounds. Celebrities like Rosie O’Donnell and Amy Schumer also credited the diabetes drug.
GLP-1 prescriptions surge in US: 7 study notes
In 2024, 4% of U.S. adults were prescribed a GLP-1 therapy — a 363.7% increase from 0.9% in 2019, according to a Fair Health analysis of more than 51 billion commercial claim records. Fair Health also found that, over those six years, the percentage of adults with a GLP-1 prescription for obesity or overweight increased […]